(CercleFinance.com) – OSE Immunotherapeutics presented on Wednesday, in collaboration with its German partner Boehringer Ingelheim, the first results of a phase 1 clinical study concerning its BI 765063 antibody in advanced solid tumors.
According to OSE, the biomarker analyzes resulting from the study made it possible to characterize its impact both on the immune cells of the peripheral blood and on the tumor microenvironment.
These early analyses, carried out in peripheral blood and on biopsies of solid tumors, notably showed ‘encouraging’ signs linked to its mode of action, in particular an increase in infiltration into the tumor and activation of T cells. CD8+.
For the biotechnology company, these new data confirm the preclinical results, which had shown that the product allowed the T lymphocytes initially excluded from the tumor to penetrate within it and play their cytotoxic role there.
These results have been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting next month in New Orleans, Louisiana.
As a reminder, Boehringer Ingelheim has obtained the exclusive rights to BI 765063 under the license and collaboration agreement.
On the Paris Stock Exchange, OSE Immunotherapeutics shares posted a gain of more than 15% on Wednesday morning following these announcements.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
